Syntara Ltd (ASX:SNT, OTC:PMXSF), formerly Pharmaxis Ltd, has dosed the first patient in a phase two clinical trial assessing its pan-LOX inhibitor SNT-5505.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, June 14, 2023 MorphoS.
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
14.06.2023 / 08:39. | June 14, 2023